Benjamin M. Hiller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin M. Hiller has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Christopher W. McMahon
FUJIFILM Cellular Dynamics, Inc., Madison, Wisconsin, USA
2 shared publications- David J. Marmion
Parkinson’s Disease Research Unit, Department of Neurobiology, Barrow Neurological Institute, Phoenix, USA
2 shared publications - Jeffrey H. Kordower
ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, AZ, United States
2 shared publications Carrie A. Chavez
FUJIFILM Cellular Dynamics, Inc., Madison, Wisconsin, USA
1 shared publicationCayla A. Thompson
FUJIFILM Cellular Dynamics, Inc., Madison, Wisconsin, USA
1 shared publicationD. James Surmeier
Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
1 shared publication
Latest Publications
- Open Access
- 30 September 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (2) , 278-290
Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo
Nongenetic methodologies to reduce undesirable proliferation would be valuable when generating dopamine neurons from stem cells for transplantation in Parkinson's disease (PD). To this end, we modified an established method for controlled differentiation of human induced pluripotent stem cells (iPSCs) into midbrain dopamine neurons using two distinct methods: omission of FGF8 or the in-process use of the DNA cross-linker mitomycin-C (MMC). We transplanted the cells to athymic rats with unilateral 6-hydroxydopamine lesions and monitored long-term survival and function of the grafts. Transplants of cells manufactured using MMC had low proliferation while still permitting robust survival and function comparable to that seen with transplanted dopamine neurons derived using genetic drug selection. Conversely, cells manufactured without FGF8 survived transplantation but exhibited poor in vivo function. Our results suggest that MMC can be used to reduce the number of proliferative cells in stem cell-derived postmitotic neuron preparations for use in PD cell therapy.
- 30 September 2020
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 10 (2) , 278-290
Open AccessMitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo
Nongenetic methodologies to reduce undesirable proliferation would be valuable when generating dopamine neurons from stem cells for transplantation in Parkinson's disease (PD). To this end, we modified an established method for controlled differentiation of human induced pluripotent stem cells (iPSCs) into midbrain dopamine neurons using two distinct methods: omission of FGF8 or the in-process use of the DNA cross-linker mitomycin-C (MMC). We transplanted the cells to athymic rats with unilateral 6-hydroxydopamine lesions and monitored long-term survival and function of the grafts. Transplants of cells manufactured using MMC had low proliferation while still permitting robust survival and function comparable to that seen with transplanted dopamine neurons derived using genetic drug selection. Conversely, cells manufactured without FGF8 survived transplantation but exhibited poor in vivo function. Our results suggest that MMC can be used to reduce the number of proliferative cells in stem cell-derived postmitotic neuron preparations for use in PD cell therapy.
- Open Access
- 1 July 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 9 (1) , 149-161
Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo
- 1 July 2017
- Published by Elsevier in Stem Cell Reports
- Vol. 9 (1) , 149-161
Open AccessCryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo